Bio Farma Group’s Cross-Sector Collaboration Expands Global Market Access
Jakarta (ANTARA) - The Bio Farma Group is strengthening health diplomacy through cross-sector collaborations to expand global market access and enhance the competitiveness of the national pharmaceutical industry.
Commercial Director of PT Kimia Farma (Persero) Tbk, Hanadi Setiarto, stated that synergy with the Ministry of Foreign Affairs represents a strategic step in opening up global market opportunities.
“This agenda is a strategic momentum to expand global market access while strengthening Indonesia’s role in health diplomacy,” said Hanadi in his statement in Jakarta on Monday.
He added that the company continues to improve the quality and production capacity to compete at the international level.
Meanwhile, the Director of Finance and Risk Management of PT Bio Farma (Persero), Jeffri Susanto, noted that integration within the Bio Farma Group serves as the main strength in enhancing the competitiveness of the national pharmaceutical industry.
“As one ecosystem, the Bio Farma Group possesses complementary synergies, from development and production to distribution,” said Jeffri.
According to him, this integration also plays a role in strengthening national health resilience while supporting Indonesia’s expansion in the global health market.
The Bio Farma Group considers cross-sector and cross-country collaborations as key factors in driving the development of the national pharmaceutical export market.
For information, PT Bio Farma (Persero) is the parent company of the state-owned pharmaceutical holding operating in the life sciences sector, with a production capacity of more than 3.4 billion vaccine doses per year and has exported products to more than 150 countries.
In addition, PT Kimia Farma (Persero) Tbk, as part of the holding, has nine production facilities, 44 distribution branches, more than 1,000 pharmacy networks, more than 350 health clinics, and 65 medical laboratories across Indonesia.
The company affirms its commitment to continuously enhancing product competitiveness and expanding strategic collaborations to strengthen Indonesia’s position as a global health partner.